Ryan Specialty Holdings, Inc.
RYAN
$30.55
+3.00%
Ryan Specialty Holdings, Inc. is an international specialty insurance intermediary that provides wholesale brokerage, delegated underwriting, and risk management services to brokers, agents, and carriers across property, casualty, professional lines, and employee benefits. The company has established itself as a significant and specialized platform in the wholesale insurance distribution and underwriting landscape, leveraging its expertise in complex and niche risks. The current investor narrative is dominated by a severe and sustained stock price decline, reflecting deep concerns over its financial performance, high leverage, and its stark underperformance relative to the broader market, which has prompted a fundamental reassessment of its growth trajectory and business model resilience.…
RYAN
Ryan Specialty Holdings, Inc.
$30.55
RYAN 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Ryan Specialty Holdings, Inc.'s 12-month outlook, with a consensus price target around $39.72 and implied upside of +30.0% versus the current price.
Average Target
$39.72
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$24 - $40
Analyst target range
Analyst coverage is limited, with only 6 analysts providing estimates, which suggests this is a mid-cap stock with constrained institutional research interest, potentially leading to higher volatility and less efficient price discovery. The available data focuses on financial estimates rather than price targets or ratings; the consensus estimates an average EPS of $2.85 for the coming period, with a wide range from a low of $1.98 to a high of $3.73, indicating substantial uncertainty about the company's earnings recovery path and the assumptions needed to achieve it.
RYAN Technical Analysis
The stock is in a pronounced and sustained downtrend, with a 1-year price change of -52.43% and a 6-month decline of -43.74%. Trading at a current price of $30.83, it sits just 3.1% above its 52-week low of $29.91, positioning it in deeply oversold territory which may indicate a value opportunity but also reflects significant fundamental distress and negative momentum. Recent momentum remains decisively negative, with the stock down -36.14% over the past 3 months and -6.66% over the past month, indicating the downtrend is persistent and accelerating rather than showing signs of a meaningful reversal; this is starkly contrasted by the S&P 500's positive returns of 4.14% and 9.98% over the same periods, respectively. Key technical support is clearly defined at the 52-week low near $29.91, while resistance is far above at the 52-week high of $72.495; a breakdown below support would signal a continuation of the bearish trend, while any recovery would need to overcome substantial overhead supply, with the stock's extreme relative weakness (e.g., -81.47% vs. SPY over 1-year) underscoring its high idiosyncratic risk.
Beta
0.68
0.68x market volatility
Max Drawdown
-60.9%
Largest decline past year
52-Week Range
$29-$72
Price range past year
Annual Return
-54.8%
Cumulative gain past year
| Period | RYAN Return | S&P 500 |
|---|---|---|
| 1m | -8.8% | +10.4% |
| 3m | -35.8% | +5.5% |
| 6m | -46.3% | +8.0% |
| 1y | -54.8% | +28.4% |
| ytd | -39.6% | +6.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RYAN Fundamental Analysis
Revenue trajectory analysis is limited due to missing quarterly financial data, but the provided analyst estimates suggest an expected annual revenue of approximately $4.13 billion, indicating the company maintains a substantial revenue base; however, the severe stock price collapse suggests the market anticipates significant growth deceleration or fundamental challenges not captured in the point estimate. Profitability is a critical concern, with a trailing net margin of only 2.08% and an extremely high trailing P/E ratio of 103.64, which points to minimal earnings; the forward P/E of 12.04 implies the market expects a significant earnings recovery, yet the negative PEG ratio of -2.89 signals that any perceived growth is not justifying the current valuation. The balance sheet shows significant financial risk, with a debt-to-equity ratio of 5.45 indicating heavy leverage, though a current ratio of 7.51 suggests strong short-term liquidity; the return on equity of 9.78% is modest, and the combination of high debt and thin margins raises questions about the sustainability of internal cash flow generation to service its obligations.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RYAN Overvalued?
Given the company's minimal net income (implied by a net margin of 2.08%), the primary valuation metric selected is the Price-to-Sales (PS) ratio, as earnings-based metrics are distorted. Ryan Specialty trades at a trailing PS ratio of 2.15 and an EV/Sales of 2.79, which provides a cleaner view of its revenue valuation. Peer comparison data is not available in the provided dataset, preventing a quantified assessment of whether its sales multiple trades at a premium or discount to the specialty insurance intermediary sector. Historical context is also unavailable due to missing historical ratios data, so it is impossible to determine if the current PS ratio is near the top or bottom of its own historical band, limiting the interpretation of whether the current price reflects excessive pessimism or a new normal.
PE
103.6x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.4x
Enterprise Value Multiple

